Introducing SERB Pharmaceuticals
SERB Pharmaceuticals represents the combination of SERB, BTG Specialty Pharmaceuticals and Veriton Pharma to form a new, growing specialty pharmaceutical company focused on critical care and rare diseases.
We make treating complex and life-threatening conditions possible; supporting clinicians, healthcare systems and governments while offering hope to patients and their families.
Who we are
SERB began in the 1950s as Société d’Études et de Recherches Biologiques (Company for Biologic Study and Research).
Today SERB has the broadest antidote portfolio in the world, including medical countermeasures for chemical, biological, radiological and nuclear (CBRN) risks.
As a fully integrated company, we have the experience and capabilities to acquire, develop, and manufacture our medicines to the highest standards, and make them available worldwide through our secure supply chain.
Improving patients’ quality of life and offering hope is what motivates and inspires us.
Direct sales in
11 May 2023SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agentSERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ Pharmaceuticals.
02 May 2023New Publication Compares Total Vials of CroFab® and Anavip® Administered to Treat US Rattlesnake EnvenomationAnalysis shows patients treated with CroFab require fewer total vials of antivenom, and fewer administrations to achieve control, than Anavip.
02 May 2023
When Choosing Antivenom, Look at Cost Per Treatment—Not Cost Per Vial
Recent NASBR data suggests that the difference in total treatment cost between antivenom products is probably much less than healthcare providers think.Read more